| Nov 20 |
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
|
| Nov 18 |
Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?
|
| Nov 14 |
(ARGX) - Analyzing argenx's Short Interest
|
| Nov 12 |
Argenx upgraded at Wolfe on myasthenia gravis dominance
|
| Nov 11 |
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
|
| Nov 11 |
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
|
| Nov 6 |
Peering Into argenx's Recent Short Interest
|
| Nov 5 |
Why Argenx (ARGX) Might be Well Poised for a Surge
|
| Nov 5 |
argenx to Participate at Upcoming Investor Conferences
|
| Nov 4 |
Three Value Stocks Priced Below Estimated Worth In November 2024
|
